Mucocutaneous Manifestations of COVID-19 among Iraqi Patients in Al Diwaniyah Province, Iraq: Case Series Study
Abstract
Background: The relatively wide distribution of ACE2 receptors all over body tissues suggests the possibility of clinical manifestations other than that of the respiratory tract. The usual incubation period is about 14 days which is often followed by the usual respiratory symptoms and constitutional signs. Globally, additional novel manifestations, including dermatological ones have been reported.
Aim: To characterise the skin manifestations in patients with COVID-19 in Al Diwaniyah Province, mid-Euphrates region of Iraq.
Method: The present case series study included 54 patients with COVID-19 and a variety of skin manifestations. Those patients visited the dermatology unit at Al Diwaniyah teaching hospital, Al Diwaniyah province, Iraq during the period of the study. The study started in July 2020 and ended in June 2021.
Results: The most common features were those of morbilliform eruptions accounting for 18.5% of cases followed by urticarial lesions accounting for 13.0% of cases for followed by ecchymotic pruritic lesion (11.1%). Other features such as oral ulceration and vesicular lesions were also seen in 9.3% of cases. All the body was involved in 29.6% followed by tongue and lip involvement. Morbilliform eruption was the most common diagnosis followed by acute urticaria, herpes simplex, leukocytoclastic vasculitis and then by a variety of other skin manifestations.
Conclusion: Skin manifestations in association with COVID-19 were highly variable with onset and duration which could be due to infection, drug reaction or immune mechanisms.
How to cite this article:
Bdaiwi SN, Abdul-Saheb RH. Mucocutaneous Manifestations of COVID-19 among Iraqi Patients in Al Diwaniyah Province, Iraq: Case Series Study. Special Issue - COVID-19 & Other Communicable Disease. 2022;239-244.
DOI: https://doi.org/10.24321/0019.5138.202236
References
Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy. 2020 Mar;5:6. [PubMed] [Google Scholar]
Allam Z. The first 50 days of COVID-19: a detailed chronological timeline and extensive review of literature documenting the pandemic. In: Surveying the Covid-19 pandemic and its implications. Elsevier; 2020. p. 1-7. [Google Scholar]
Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020 Oct;61(3):E304-12. [PubMed] [Google Scholar]
Sheleme T, Bekele F, Ayela T. Clinical presentation of patients infected with Coronavirus Disease 19: a systematic review. Infect Dis (Auckl). 2020 Sep;13:1178633720952076. [PubMed] [Google Scholar]
Vannabouathong C, Devji T, Ekhtiari S, Chang Y, Phillips SA, Zhu M, Chagla Z, Main C, Bhandari M. Novel Coronavirus COVID-19: current evidence and evolving strategies. J Bone Joint Surg Am. 2020 May;102(9):734-44. [PubMed] [Google Scholar]
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020 Mar;91(1):157-60. [PubMed] [Google Scholar]
Singh H, Kaur H, Singh K, Sen CK. Cutaneous manifestations of COVID-19: a systematic review. Adv Wound Care (New Rochelle). 2021 Feb;10(2):51-80. [PubMed] [Google Scholar]
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res. 2020 Mar;7:11. [PubMed] [Google Scholar]
Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-19. [PubMed] [Google Scholar]
Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, van der Voort PH, Mulder DJ, van Goor H. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020 Jul;251(3):228-48. [PubMed] [Google Scholar]
Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020 Apr;9:45. [PubMed] [Google Scholar]
Xue X, Mi Z, Wang Z, Pang Z, Liu H, Zhang F. High expression of ACE2 on keratinocytes reveals skin as a potential target for SARS-CoV-2. J Invest Dermatol. 2021 Jan;141(1):206-9.e1. [PubMed] [Google Scholar]
Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020 May;34:e212-3. [PubMed] [Google Scholar]
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr;382:1708-20. [PubMed] [Google Scholar]
Drago F, Ciccarese G, Gasparini G, Cogorno L, Javor S, Toniolo A, Broccolo F. Contemporary infectious exanthems: an update. Future Microbiol. 2017 Feb;12:171-93. [PubMed] [Google Scholar]
Rongioletti F. SARS-CoV, Mers-CoV and COVID-19: what differences from a dermatological viewpoint? J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e581-2. [PubMed] [Google Scholar]
Ely JW, Stone MS. The generalized rash: part I. Differential diagnosis. Am Fam Physician. 2010 Mar;81:726-34. [PubMed] [Google Scholar]
Galván Casas C, Català A, Carretero Hernández G, RodrÃguez-Jiménez P, Fernández-Nieto D, RodrÃguez-Villa Lario A, Navarro Fernández I, Ruiz-Villaverde R, Falkenhain-López D, Llamas Velasco M, GarcÃa-GavÃn J, Baniandrés O, González-Cruz C, Morillas-Lahuerta V, Cubiró X, Figueras Nart I, Selda-Enriquez G, Romanà J, Fustà -Novell X, Melian-Olivera A, Roncero Riesco M, Burgos-Blasco P, Sola Ortigosa J, Feito Rodriguez M, GarcÃa-Doval I. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020 Jul;183:71-7. [PubMed] [Google Scholar]
Diotallevi F, Campanati A, Bianchelli T, Bobyr I, Luchetti MM, Marconi B, Martina E, Radi G, Offidani A. Skin involvement in SARS-CoV-2 infection: case series. J Med Virol. 2020 Nov;92(11):2332-4. [PubMed] [Google Scholar]
Mohammed ZI, Qasim MT. Hormonal profile of men during infertility. Biochem Cell Arch. 2021;Supplement 1:2895-8.
Tahmasebi S, Qasim MT, Krivenkova MV, Zekiy AO, Thangavelu L, Aravindhan S, Izadi M, Jadidi-Niaragh F, Ghaebi M, Aslani S, Aghebat-Maleki L, Ahmadi M, Roshangar L. The effects of Oxygen-Ozone therapy on regulatory T-cell responses in multiple sclerosis patients. Cell Biol Int. 2021 Jul;45(7):1498-509. [PubMed] [Google Scholar]
Shabgah AG, Qasim MT, Mostafavi SM, Zekiy AO, Ezzatifar F, Ahmadi M, Haftcheshmeh SM, Navashenaq JG. CXC chemokine ligand 16: a Swiss army knife chemokine in cancer. Expert Rev Mol Med. 2021 Apr;23:e4. [PubMed] [Google Scholar]
Herrero-Moyano M, Capusan TM, Andreu-Barasoain M, Alcántara-González J, Ruano-Del Salado M, Sánchez-Largo Uceda ME, Calzado-Villarreal L, Pérez-González Y. A clinicopathological study of eight patients with COVID-19 pneumonia and a late-onset exanthema. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e460-4. [PubMed] [Google Scholar]
Tursen U, Tursen B, Lotti T. Cutaneous side effects of the potential COVID-19 drugs. Dermatol Ther. 2020 Jul;33(4):e13476. [PubMed] [Google Scholar]
Copyright (c) 2022 Author's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
